Research Products. Liquidia will be responsible for manufacture and supply in accordance with GMP and GSK’s quality standards all of the PRINT Materials, Liquidia Respiratory Product and/or Research Products (as applicable) reasonably required by GSK, its Affiliates and sublicensees for use in the development of the Research Products after the exercise of the Inhaled Option or Liquidia Respiratory Option and before the commencement of the first pivotal Clinical Trial for which Regulatory Authorities require commercial grade supply of the Liquidia Respiratory Product or Research Product, subject to and in accordance with the commercially reasonable terms and conditions of a clinical development and supply agreement to be mutually agreed and negotiated by the Parties (the “Development Supply Agreement”). The Parties will use reasonable efforts to negotiate the commercially reasonable terms of the Development Supply Agreement promptly after the exercise of the Inhaled Option and/or Liquidia Respiratory Option, as the case may be, which shall include provisions consistent with GSK’s rights set forth in Section 5.2(c)(ii) in the event that Liquidia cannot or does not supply in accordance with the terms of such Development Supply Agreement; provided, that if the Parties cannot agree to the terms of a Development Supply Agreement then GSK’s right to make and have made PRINT Materials, Liquidia Respiratory Product and/or Research Products as set forth in Sections 5.2(a), 5.2(b) and 5.2(c)(ii) shall apply.
Research Products. From time to time, COMPANY may request, in writing, that DPT evaluate, develop, manufacture, test and/or provide price quotations for certain new items which may become Products (hereinafter referred to as “Research Products”) on behalf of COMPANY. If DPT agrees to perform such services, DPT shall so notify COMPANY within sixty (60) days of its receipt of COMPANY’s request. To the extent that DPT agrees to perform any services hereunder for COMPANY, DPT shall only be obligated to act in good faith and to use reasonable efforts to accomplish the desired results as outlined in a mutually agreed upon Project Protocol. Nothing herein shall obligate DPT to achieve any specific results and DPT makes no warranties or representations that it will be able to achieve the desired results.
Research Products. The Parties agree to make mutually acceptable arrangements for the disposition of any unique or hard-to-replace research products.
Research Products. Wit Group shall provide any and all research products in connection with the operation of the underwriting, investment banking and financial services business of Wit Group (to a comparable extent as the written research products provided to Wit Group's institutional clients, subject to the last sentence of this paragraph) to E Group for the benefit and use by the retail customers of E Group, subject to E Group's reasonable discretion and at no cost or expense to E Group or its Affiliates or such retail customers. E Group and Wit Group will cooperate with each other to develop promptly after the closing of the Merger the regulatory and technological processes and mechanisms for providing such research to retail customers of E Group at the same time as it is provided to institutional clients of Wit Group, reflecting the parties' intent to place retail and institutional recipients of such research products in the same position from a time perspective. Wit Group shall cooperate with E Group to develop such research products for the tailored use by retail customers, making such adjustments and modifications as are reasonably necessary. Wit Group shall not distribute any such research products to Competitors of E Group without E*TRADE's prior written consent. "
Research Products. NVS will have the right, in its sole discretion, to Research, Develop, Manufacture, and Commercialize any and all Selected Research Compounds and Research Products, subject to Sections 3.3 and 6.2(a) and Article 9. For clarity, a Research Target will cease to remain a Research Target under this Agreement, and all Selected Research Compounds and Research Products will cease to remain the same under this Agreement, if NVS elects in writing, pursuant to Section 15.2(c), not to further Research or Develop any Selected Research Compound or Research Product for such Research Target.
Research Products. Subject to the terms and conditions of this Agreement, Pliant hereby grants to NVS and its Affiliates (i) an exclusive (even as to Pliant and its Affiliates), transferrable (pursuant to Section 19.1), sublicensable (pursuant to Section 4.1(f)) license under the Pliant Technology and Joint Technology to Develop, Manufacture and Commercialize Selected Research Compounds and Research Products in the Field in the Territory; and (ii) a co-exclusive (with Pliant and its Affiliates), transferrable (pursuant to Section 19.1), sublicensable (pursuant to Section 4.1(f)) license under the Pliant Technology and Joint Technology, to Research the Candidate Targets, Research Targets, and to Research the Research Compounds or Selected Research Compounds (as applicable) for each Research Target; which co-exclusive license shall become exclusive to NVS, solely with respect to Selected Research Compounds, effective as of the Development Candidate Selection Date for such Research Target. For clarity, such co-exclusivity retains for Pliant solely the right to conduct: (x) those Research Plan Activities under the applicable Research Plan; and (y) those Manufacturing activities in accordance with the applicable Research Plan, in each case of (x) and (y), undertaken pursuant to the express terms of this Agreement.
Research Products. (a) Responsibility and Costs for Regulatory Matters. NVS will be solely responsible, at its sole cost and expense, for determining the regulatory plans and strategies and for all other regulatory matters relating to all Research Products, including: (i) overseeing, monitoring and coordinating all regulatory actions, communications and filings with, and submissions to, each Regulatory Authority with respect to such Research Products; and (ii) interfacing, corresponding, and meeting with each Regulatory Authority. Pliant will fully cooperate with and provide assistance to NVS and its designees upon NVS's request in connection with filings to any Regulatory Authority relating to the Research Product(s), including by executing any required documents, providing access to personnel and providing NVS with copies of all reasonably required documentation.
Research Products. Subject to Section 10.6 and Section 10.7, NVS shall pay to Pliant royalties, during the Royalty Term, on a Research Product-by-Research Product basis, on Annual Net Sales for each Research Product in the Territory at the royalty rates set forth below
Research Products. The APPLICANT intends to present research findings in written and/or oral format. (If checked, continue.)
A. The APPLICANT will present a first draft of either preliminary or endmost research findings generated under this agreement and related methodology to the PVUSD REPRESENTATIVE at least six weeks prior to any written or oral presentation thereof. The draft must identify the intended audience and cite specific forums (e.g., journals, conferences, dissertation) in which the findings will be presented.
B. The PVUSD REPRESENTATIVE agrees to take no longer than two weeks from receipt to review the first draft of either preliminary or endmost findings, cite inaccuracies, and/or offer revisions that comport with rigorous research methodology.
C. The APPLICANT agrees to submit the final research product to the district prior to any written or oral presentation of endmost findings and—after presentation or dissemination—an electronic copy of the final version for posting on the district website.
Research Products. Wit Group shall provide any and all research products in connection with the operation of the underwriting, investment banking and financial services business of Wit Group (to a comparable extent as the written research products
